By binding the substance to a radiotracer, experts were able to improve the accuracy of identifying these tumors by as much as 30% compared to the standard of care.

The premixed embolic agent is designed to embolize hypervascular tumors and occlude blood flow in a patient's peripheral blood vessels. It was recalled in April due to safety concerns.

The news comes just days after CMS confirmed these technologies would start receiving expanded Medicare coverage in November. HeartFlow and other AI vendors have already shared their excitement over the decision. 

The new policy goes into effect in November, improving Medicare coverage for a technology that has rapidly gained momentum in recent years.

Researchers examined the brains of bilingual and monolingual people using fMRI, only to find improved communication between isolated regions in those who learn a second language at a young age.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Researchers have used 7T MRI to demonstrate that former COVID-19 inpatients are susceptible to persistent brainstem abnormalities associated with long-haul COVID symptoms.

The popular AI chatbot tends to over-order X-rays, prescribe too many antibiotics and admit too many patients to the hospital when compared with a resident emergency department physician.